Lesage Anne 4
4 · Pharvaris N.V. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Pharvaris (PHVS) Anne Lesage Exercises Options and Sells Shares
What Happened
- Anne Lesage, Chief Early Development at Pharvaris (PHVS), exercised stock options and sold shares on June 25, 2026. She exercised (M) option tranches totaling 3,600 underlying shares (1,400 at $2.59 and 900 at $8.05; plus 2,300/1,400/900 reported as derivative-related dispositions) and sold 4,600 shares in the open market in two blocks of 2,300 shares each at a weighted average price of $35.12. The two sales totaled approximately $161,561 (reported as $80,775 and $80,786). Some option-related shares were surrendered/treated as derivative dispositions at $0.00 in connection with the cashless exercise.
Key Details
- Transaction date: June 25, 2026.
- Option exercises recorded: 1,400 shares @ $2.59 (cost $3,626) and 900 shares @ $8.05 (cost $7,245). Additional derivative disposals of 1,400 and 900 shares at $0.00 relate to the exercise/cashless mechanics.
- Open‑market sales: 4,600 shares (two lots of 2,300) at a weighted average price of $35.12; sale prices ranged $35.00–$35.30 per footnote. Total proceeds ≈ $161,561.
- Plan and mechanics: Sales were made pursuant to a Rule 10b5‑1 trading plan (scheduled exercise and sale); the shares sold were in connection with a cashless exercise of options per the filing.
- Shares owned after the transactions: not specified in the provided filing excerpt.
- Filing timeliness: Reported on June 29, 2026 for transactions on June 25, 2026 — the filing appears timely (not marked late).
Context
- This was an option exercise plus immediate sale (cashless exercise) executed under a pre‑arranged 10b5‑1 plan; such sales are typically pre-scheduled and are not direct, discretionary sales by the insider at the time of sale.
- Footnotes: GrayMatters Consulting B.V. is an entity controlled by Dr. Lesage (F3). Vesting schedules noted for the option grants: one grant vested 25% on Apr 6, 2024 with monthly vesting thereafter (F4); another vested 25% on Feb 3, 2021 with monthly vesting thereafter (F5).
- Transaction codes: M = option exercise/conversion, S = open market sale; zero-dollar derivative dispositions reflect shares surrendered or used in the cashless exercise/tax withholding.
Insider Transaction Report
Form 4
Pharvaris N.V.PHVS
Lesage Anne
Chief Early Development
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-25$2.59/sh+1,400$3,626→ 57,850 total - Exercise/Conversion
Common Stock
[F1]2026-06-25$8.05/sh+900$7,245→ 58,750 total - Sale
Common Stock
[F1][F2]2026-06-25$35.12/sh−2,300$80,775→ 56,450 total - Sale
Common Stock
[F1][F2][F3]2026-06-25$35.12/sh−2,300$80,786→ 131,669 total(indirect: By GrayMatters Consulting BVBA) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]2026-06-25−900→ 74,100 totalExercise: $8.05Exp: 2033-04-06→ Common Stock (900 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-06-25−1,400→ 7,072 totalExercise: $2.59Exp: 2030-01-01→ Common Stock (1,400 underlying)
Footnotes (5)
- [F1]This is a scheduled exercise and sale from 10b5-1 trading plan.
- [F2]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]GrayMatters Consulting B.V., an entity controlled by Dr. Lesage
- [F4]25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
- [F5]25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
Signature
/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage|2026-06-29